NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Price Target & More

$55.12 +0.11 (+0.20 %)
(As of 04/26/2018 07:12 AM ET)
Previous Close$55.01
Today's Range$54.15 - $55.82
52-Week Range$45.05 - $97.15
Volume137,300 shs
Average Volume233,505 shs
Market Capitalization$817.56 million
P/E Ratio15.03
Dividend YieldN/A
Beta1.38

About Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Debt-to-Equity Ratio0.24%
Current Ratio3.99%
Quick Ratio3.88%

Price-To-Earnings

Trailing P/E Ratio15.03
Forward P/E Ratio22.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$236.71 million
Price / Sales3.46
Cash Flow$3.8654 per share
Price / Cash14.26
Book Value$12.01 per share
Price / Book4.59

Profitability

EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins21.94%
Return on Equity34.16%
Return on Assets23.74%

Miscellaneous

Employees108
Outstanding Shares14,860,000

How to Become a New Pot Stock Millionaire

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals declared that its board has approved a share buyback plan on Thursday, August 10th 2017, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 13.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals (NASDAQ:EGRX) released its quarterly earnings results on Monday, February, 26th. The specialty pharmaceutical company reported $0.84 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.00 by $0.16. The specialty pharmaceutical company earned $46.80 million during the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. Eagle Pharmaceuticals's quarterly revenue was down 42.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.52 EPS. View Eagle Pharmaceuticals' Earnings History.

What price target have analysts set for EGRX?

3 Wall Street analysts have issued 1-year price targets for Eagle Pharmaceuticals' shares. Their predictions range from $40.00 to $79.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $63.3333 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (3/1/2018)
  • 2. Mizuho analysts commented, "We attribute the miss to lower revenues and higher COGS. Eagle previously announced that it plans to initiate another pivotal trial of Ryanodex in exertional heat stroke (EHS) at the Hajj pilgrimage in August. We view this initiative as largely unproductive because identifying appropriate patients and trial execution could prove challenging yet again. However, enrollment in the fulvestrant trial was faster than expected (data could be a catalyst in the coming months) and Eagle has advanced one of its ANDA filings, which are slight positives to the story. In the past week we saw announcements that two senior executives (Chief Scientific Officer and General Counsel) have left Eagle, which we believe bodes poorly for the future outlook of the company. We reiterate our Underperform rating on the stock and will update thoughts after the call. We summarize 4Q:17 performance below." (2/26/2018)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, Chief Exec. Officer and Director (Age 58)
  • Mr. David M. Pernock, Pres and Chief Commercial Officer (Age 65)
  • Dr. Adrian Hepner M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 57)
  • Mr. Pete A. Meyers, Chief Financial Officer and Principal Accounting Officer (Age 48)
  • Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News coverage about EGRX stock has trended somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 47.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $55.12.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $817.56 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eagle Pharmaceuticals (NASDAQ:EGRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Eagle Pharmaceuticals in the last 12 months. Their average twelve-month price target is $63.3333, suggesting that the stock has a possible upside of 14.90%. The high price target for EGRX is $79.00 and the low price target for EGRX is $40.00. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.332.332.50
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $63.3333$63.3333$62.3333$72.50
Price Target Upside: 14.90% upside20.91% upside12.68% upside34.06% upside

Eagle Pharmaceuticals (NASDAQ:EGRX) Consensus Price Target History

Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018MizuhoReiterated RatingUnderperform -> Underperform$37.00 -> $40.00MediumView Rating Details
2/26/2018Royal Bank of CanadaSet Price TargetBuy$71.00MediumView Rating Details
1/30/2018Piper JaffrayReiterated RatingBuy$79.00MediumView Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 -> $97.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Eagle Pharmaceuticals (NASDAQ:EGRX) Earnings History and Estimates Chart

Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Earnings Estimates

2018 EPS Consensus Estimate: $2.45
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.33$0.33$0.33
Q2 20181$0.77$0.77$0.77
Q3 20181$0.59$0.59$0.59
Q4 20181$0.76$0.76$0.76

Eagle Pharmaceuticals (NASDAQ EGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018Q4 2017$1.00$0.84$53.65 million$46.80 millionViewListenView Earnings Details
11/8/2017Q3 2017$0.57$1.07$51.63 million$63.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.51$0.33$52.52 million$50.10 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.44$1.42$70.10 million$76.80 millionViewListenView Earnings Details
3/1/2017Q416$2.24$3.52$86.13 million$81.10 millionViewListenView Earnings Details
11/9/2016Q316$0.71$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.53$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.59)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.56$1.31$3.41 million$36.30 millionViewListenView Earnings Details
2/17/2015Q4 2014($0.39)$3.12 million$5.60 millionViewN/AView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.90 million$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.39)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eagle Pharmaceuticals (NASDAQ:EGRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.50%
Insider Trading History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Sander A FlaumDirectorSell2,340$53.94$126,219.60View SEC Filing  
8/16/2017Pete A MeyersCFOBuy350$55.45$19,407.50700View SEC Filing  
8/9/2017Douglas L BraunsteinDirectorBuy20,400$49.07$1,001,028.00View SEC Filing  
6/12/2017Pete A MeyersCFOBuy350$71.49$25,021.50350View SEC Filing  
5/19/2017David PernockInsiderBuy255$79.69$20,320.95966View SEC Filing  
5/16/2017David PernockInsiderBuy200$82.24$16,448.00711View SEC Filing  
4/25/2017Proquest Investments Iv, L.P.Major ShareholderSell54,180$88.38$4,788,428.40View SEC Filing  
4/3/2017Proquest Investments Iv, L.P.Major ShareholderSell91,332$83.09$7,588,775.88View SEC Filing  
3/29/2017Proquest Investments Iv, L.P.Major ShareholderSell106,468$83.01$8,837,908.68View SEC Filing  
3/28/2017Proquest Investments Iv, L.P.Major ShareholderSell6,182$83.02$513,229.64View SEC Filing  
3/27/2017Proquest Investments Iv, L.P.Major ShareholderSell39,431$83.00$3,272,773.00View SEC Filing  
3/23/2017Proquest Investments Iv, L.P.Major ShareholderSell1,200$83.05$99,660.00View SEC Filing  
3/23/2017Steven L KrillEVPSell14,125$81.07$1,145,113.755,023View SEC Filing  
3/22/2017Richard A EdlinDirectorBuy6,000$79.44$476,640.0029,400View SEC Filing  
3/21/2017David PernockInsiderBuy61$83.98$5,122.78511View SEC Filing  
3/20/2017Proquest Investments Iv, L.P.Major ShareholderSell100,000$82.06$8,206,000.00View SEC Filing  
3/9/2017David PernockInsiderBuy450$77.84$35,028.00450View SEC Filing  
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.0023,324View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.0011,374View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.951,369,946View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.001,000View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.801,420,491View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.2516,374View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.501,453,400View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.571,467,450View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.761,486,789View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.751,504,667View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eagle Pharmaceuticals (NASDAQ EGRX) News Headlines

Source:
DateHeadline
BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to SellBidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Sell
www.americanbankingnews.com - April 18 at 12:16 PM
William Blair Analysts Reduce Earnings Estimates for Eagle Pharmaceuticals (EGRX)William Blair Analysts Reduce Earnings Estimates for Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - April 18 at 7:58 AM
Eagle Pharmaceuticals (EGRX) to Post Q2 2018 Earnings of $0.77 Per Share, William Blair ForecastsEagle Pharmaceuticals (EGRX) to Post Q2 2018 Earnings of $0.77 Per Share, William Blair Forecasts
www.americanbankingnews.com - April 17 at 6:45 AM
Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDAEagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA
finance.yahoo.com - April 16 at 8:56 AM
Mizuho Trims Eagle Pharmaceuticals (EGRX) Target Price to $40.00Mizuho Trims Eagle Pharmaceuticals (EGRX) Target Price to $40.00
www.americanbankingnews.com - April 15 at 5:39 PM
Eagle Pharmaceuticals (EGRX) Price Target Cut to $81.00Eagle Pharmaceuticals (EGRX) Price Target Cut to $81.00
www.americanbankingnews.com - April 15 at 5:06 PM
Eagle Pharmaceuticals (EGRX) Cut to Strong Sell at BidaskClubEagle Pharmaceuticals (EGRX) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - April 14 at 11:26 PM
 Brokerages Expect Eagle Pharmaceuticals (EGRX) Will Post Quarterly Sales of $49.18 Million Brokerages Expect Eagle Pharmaceuticals (EGRX) Will Post Quarterly Sales of $49.18 Million
www.americanbankingnews.com - April 14 at 3:51 AM
Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Buy"Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 13 at 1:35 PM
 Brokerages Expect Eagle Pharmaceuticals (EGRX) to Announce $0.84 Earnings Per Share Brokerages Expect Eagle Pharmaceuticals (EGRX) to Announce $0.84 Earnings Per Share
www.americanbankingnews.com - April 12 at 11:19 AM
Eagle Pharmaceuticals (EGRX) Upgraded at ValuEngineEagle Pharmaceuticals (EGRX) Upgraded at ValuEngine
www.americanbankingnews.com - April 8 at 12:54 PM
Head to Head Survey: Mersana Therapeutics (MRSN) versus Eagle Pharmaceuticals (EGRX)Head to Head Survey: Mersana Therapeutics (MRSN) versus Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - April 4 at 5:22 PM
Eagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from AnalystsEagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 11:38 AM
Eagle Pharmaceuticals (EGRX) Given "Outperform" Rating at Royal Bank of CanadaEagle Pharmaceuticals (EGRX) Given "Outperform" Rating at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 6:34 PM
Eagle Pharmaceuticals (EGRX) Lowered to Hold at ValuEngineEagle Pharmaceuticals (EGRX) Lowered to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
Eagle Pharmaceuticals (EGRX) Secures New Patent for Eagle BiologicsEagle Pharmaceuticals (EGRX) Secures New Patent for Eagle Biologics
www.streetinsider.com - March 28 at 4:46 PM
Eagle Pharmaceuticals (EGRX) Lowered to "Hold" at BidaskClubEagle Pharmaceuticals (EGRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
Eagle Pharmaceuticals Announces New Patent for Eagle BiologicsEagle Pharmaceuticals Announces New Patent for Eagle Biologics
finance.yahoo.com - March 27 at 9:23 AM
Eagle Pharmaceuticals (EGRX) Given Buy Rating at Piper JaffrayEagle Pharmaceuticals (EGRX) Given Buy Rating at Piper Jaffray
www.americanbankingnews.com - March 26 at 1:26 PM
ValuEngine Lowers Eagle Pharmaceuticals (EGRX) to HoldValuEngine Lowers Eagle Pharmaceuticals (EGRX) to Hold
www.americanbankingnews.com - March 25 at 6:26 PM
BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to HoldBidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Hold
www.americanbankingnews.com - March 24 at 4:30 PM
Head to Head Survey: Eagle Pharmaceuticals (EGRX) vs. Tactile Systems Technology (TCMD)Head to Head Survey: Eagle Pharmaceuticals (EGRX) vs. Tactile Systems Technology (TCMD)
www.americanbankingnews.com - March 21 at 11:10 PM
Eagle Pharmaceuticals (EGRX) Rating Reiterated by MizuhoEagle Pharmaceuticals (EGRX) Rating Reiterated by Mizuho
www.americanbankingnews.com - March 21 at 7:48 PM
Eagle Pharmaceuticals: New Clarity On Past Overhangs Reveals Solid Value Opportunity - Seeking AlphaEagle Pharmaceuticals: New Clarity On Past Overhangs Reveals Solid Value Opportunity - Seeking Alpha
seekingalpha.com - March 9 at 5:57 PM
Eagle Pharmaceuticals Inc (EGRX) Director Sells $126,219.60 in StockEagle Pharmaceuticals Inc (EGRX) Director Sells $126,219.60 in Stock
www.americanbankingnews.com - March 7 at 7:12 PM
Eagle Pharmaceuticals Inc (EGRX) Receives Consensus Recommendation of "Hold" from AnalystsEagle Pharmaceuticals Inc (EGRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 7 at 11:58 AM
Eagle Pharmaceuticals Inc (EGRX) Shares Bought by Lazard Asset Management LLCEagle Pharmaceuticals Inc (EGRX) Shares Bought by Lazard Asset Management LLC
www.americanbankingnews.com - March 6 at 12:16 PM
Blog Exposure - Mylan Plans to Launch Two New HIV Treatments in the USBlog Exposure - Mylan Plans to Launch Two New HIV Treatments in the US
finance.yahoo.com - March 6 at 8:56 AM
Spark Investment Management LLC Buys Shares of 24,200 Eagle Pharmaceuticals Inc (EGRX)Spark Investment Management LLC Buys Shares of 24,200 Eagle Pharmaceuticals Inc (EGRX)
www.americanbankingnews.com - March 3 at 12:36 PM
Globeflex Capital L P Takes $1.40 Million Position in Eagle Pharmaceuticals Inc (EGRX)Globeflex Capital L P Takes $1.40 Million Position in Eagle Pharmaceuticals Inc (EGRX)
www.americanbankingnews.com - March 2 at 4:18 PM
Eagle Pharmaceuticals Inc (EGRX) Shares Bought by Royce & Associates LPEagle Pharmaceuticals Inc (EGRX) Shares Bought by Royce & Associates LP
www.americanbankingnews.com - March 2 at 10:44 AM
Eagle Pharmaceuticals (EGRX) Cut to "Strong Sell" at Zacks Investment ResearchEagle Pharmaceuticals (EGRX) Cut to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - March 1 at 9:52 PM
New Strong Sell Stocks for March 1stNew Strong Sell Stocks for March 1st
finance.yahoo.com - March 1 at 8:50 AM
Eagle Pharmaceuticals Inc (EGRX) to Post Q1 2018 Earnings of $0.81 Per Share, William Blair ForecastsEagle Pharmaceuticals Inc (EGRX) to Post Q1 2018 Earnings of $0.81 Per Share, William Blair Forecasts
www.americanbankingnews.com - March 1 at 8:36 AM
Arrowstreet Capital Limited Partnership Decreases Holdings in Eagle Pharmaceuticals Inc (EGRX)Arrowstreet Capital Limited Partnership Decreases Holdings in Eagle Pharmaceuticals Inc (EGRX)
www.americanbankingnews.com - March 1 at 4:34 AM
William Blair Comments on Eagle Pharmaceuticals Incs Q2 2018 Earnings (EGRX)William Blair Comments on Eagle Pharmaceuticals Inc's Q2 2018 Earnings (EGRX)
www.americanbankingnews.com - February 28 at 9:18 AM
Eagle Pharmaceuticals (EGRX) Q4 2017 Earnings Conference Call TranscriptEagle Pharmaceuticals (EGRX) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - February 27 at 5:21 PM
Eagle Pharmaceuticals (EGRX) Given a $71.00 Price Target at Royal Bank of CanadaEagle Pharmaceuticals (EGRX) Given a $71.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - February 27 at 3:32 PM
Eagle Pharmaceuticals (EGRX) Releases  Earnings Results, Misses Expectations By $0.16 EPSEagle Pharmaceuticals (EGRX) Releases Earnings Results, Misses Expectations By $0.16 EPS
www.americanbankingnews.com - February 27 at 9:46 AM
Eagle Pharmaceuticals (EGRX) "Sell" Rating Reaffirmed at MizuhoEagle Pharmaceuticals' (EGRX) "Sell" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - February 26 at 4:20 PM
Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 ResultsEagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 26 at 8:56 AM
JW Asset Management LLC Decreases Position in Eagle Pharmaceuticals Inc (EGRX)JW Asset Management LLC Decreases Position in Eagle Pharmaceuticals Inc (EGRX)
www.americanbankingnews.com - February 26 at 8:52 AM
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018
finance.yahoo.com - February 15 at 4:52 PM
Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare ConferenceEagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 13 at 9:33 AM
Eagle Pharmaceuticals (EGRX) Upgraded to Buy by BidaskClubEagle Pharmaceuticals (EGRX) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - February 11 at 10:16 PM
Eagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from BrokeragesEagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 11:40 AM
Eagle Pharmaceuticals (EGRX) Announces Fifth Orange Book Listed Patent for RYANODEXEagle Pharmaceuticals (EGRX) Announces Fifth Orange Book Listed Patent for RYANODEX
www.streetinsider.com - February 8 at 8:39 AM
Eagle Pharmaceuticals (EGRX) & DARA Biosciences (DARA) Critical AnalysisEagle Pharmaceuticals (EGRX) & DARA Biosciences (DARA) Critical Analysis
www.americanbankingnews.com - February 7 at 12:00 PM
Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEXEagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX
finance.yahoo.com - February 7 at 9:32 AM
Reviewing Eagle Pharmaceuticals (EGRX) and DARA Biosciences (DARA)Reviewing Eagle Pharmaceuticals (EGRX) and DARA Biosciences (DARA)
www.americanbankingnews.com - February 3 at 2:44 PM

SEC Filings

Eagle Pharmaceuticals (NASDAQ:EGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eagle Pharmaceuticals (NASDAQ:EGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eagle Pharmaceuticals (NASDAQ EGRX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.